Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Inclusion Criteria

• •For more information regarding Bristol-Myers Squibb (BMS) clinical trial participation, please visit www.BMSStudyConnect.com.
• •Histologically confirmed hormone receptor positive (HR+) \[(estrogen receptor (ER+) and/or progesterone receptors(PgR+)\] breast cancer according to immunohistochemistry (IHC)
• •Measureable or evaluable-only disease
• •human epidermal growth factor receptor 2+ (HER2+) or HER2- breast cancer
• •Males and females ≥18 years of age
• •Females are post menopausal or surgically sterile
• •Recurrent or progressive advanced breast cancer (locally-advanced or metastatic), that has progressed: (a) during or within 12 months after completion of adjuvant Aromatase Inhibitor (AI) treatment OR (b) during AI treatment in advanced setting (metastatic therapy)